The Direct Factor Xa Inhibitor Rivaroxaban Passes Into Human Breast Milk

Chest

Volumn 150, Issue 1, 2016, Pages e1-e4

  Wiesen, Martin H J ^a   Blaich, Cornelia ^a   Müller, Carsten ^a   Streichert, Thomas ^a   Pfister, Roman ^a   Michels, Guido ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

breastfeeding; lactation; liquid chromatography tandem mass spectrometry; pulmonary embolism; rivaroxaban

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BROMOCRIPTINE; ENOXAPARIN; HYDROCHLOROTHIAZIDE; METOPROLOL; RAMIPRIL; RIVAROXABAN; TROPONIN T; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREAST FEEDING; BREAST MILK; BREAST MILK EXPRESSION; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; CESAREAN SECTION; CHEST TIGHTNESS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG MILK LEVEL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LIQUID CHROMATOGRAPHY; LUNG ANGIOGRAPHY; LUNG EMBOLISM; MEDICAL HISTORY; PERIPARTUM CARDIOMYOPATHY; PREGNANCY; PRIORITY JOURNAL; SOLUTIO PLACENTAE; TANDEM MASS SPECTROMETRY; TRANSTHORACIC ECHOCARDIOGRAPHY; BIOAVAILABILITY; CHEMISTRY; CHROMATOGRAPHY; CINE MAGNETIC RESONANCE IMAGING; DIAGNOSTIC IMAGING; DRUG MONITORING; LUNG; METABOLISM; ORAL DRUG ADMINISTRATION; PROCEDURES; PUERPERAL DISORDERS; PULMONARY EMBOLISM; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; BREAST FEEDING; CHROMATOGRAPHY; COMPUTED TOMOGRAPHY ANGIOGRAPHY; DRUG MONITORING; FACTOR XA INHIBITORS; FEMALE; HUMANS; LUNG; MAGNETIC RESONANCE IMAGING, CINE; MILK, HUMAN; PREGNANCY; PUERPERAL DISORDERS; PULMONARY EMBOLISM; RIVAROXABAN; TREATMENT OUTCOME;

EID: 84990055856     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.01.021     Document Type: Article

References (10)

1. 1 Bates, S.M., Greer, I.A., Middeldorp, S., et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:2 suppl (2012), e691S–e736S.
2. 2 Yeh, C.H., Gross, P.L., Weitz, J.I., Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood 124:7 (2014), 1020–1028.
3. 3 Wang, Y., Bajorek, B., New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs 14:3 (2014), 175–189.
4. 4 Blaich, C., Müller, C., Michels, G., Wiesen, M.H., Multi-analyte analysis of non-vitamin K antagonist oral anticoagulants in human plasma using tandem mass spectrometry. Clin Chem Lab Med 53:12 (2015), 1981–1990.
5. 5 Bennett, P.N., Use of the monographs on drugs. Bennett, P.N., (eds.) Drugs and Human Lactation, 2nd ed., 1996, Elsevier, Amsterdam, The Netherlands, 67–74.
6. 6 Berlin, C.M., Briggs, G.G., Drugs and chemicals in human milk. Semin Fetal Neonatal Med 10:2 (2005), 149–159.
7. 7 Ilett, K.F., Watt, F., Hackett, L.P., Kohan, R., Teoh, S., Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression. Ther Drug Monit 32:6 (2010), 704–707.
8. 8 Kearns, G.L., Abdel-Rahman, S.M., Alander, S.W., Blowey, D.L., Leeder, J.S., Kauffman, R.E., Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med 349:12 (2003), 1157–1167.
9. 9 Attard, C., Monagle, P., Kubitza, D., Ignjatovic, V., The in-vitro anticoagulant effect of rivaroxaban in neonates. Blood Coagul Fibrinolysis 25:3 (2014), 237–240.
10. 10 Stampfuss, J., Kubitza, D., Becka, M., Mueck, W., The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 51:7 (2013), 549–561.